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Conclusions: Most IABP were inserted for myocardial infarction related
indications. Over the last 4 years there was no significant difference in the rel-
ative weight of each class of indication. However, there was a trend toward a
reduction in number and proportion of patients who had an IABP inserted in
our ICU, especially in 2012. Our data show that guidelines influenced the rate
of IABP insertion in the ICU of a tertiary hospital.
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Introduction: Pulmonary embolism (PE) continues to be associated with
significant mortality despite advances in the diagnostic techniques available
for its detection. Anticoagulation remains standard treatment in PE and throm-
bolytic therapy should be the first-line treatment in patients with high-risk PE
presenting with cardiogenic shock and/or persistent arterial hypotension. 
Objective: The purpose of this study is to evaluate the interest of throm-
bolytic therapy in massive pulmonary embolism.
Materials and results: We report seven cases of massive pulmonary embo-
lism with poor hemodynamic states. They were 6 women and one man. The
mean age was 53 years [28;75]. The diagnosis of PE was confirmed by trans-
thoracic echocardiography in 2 patients showing multiple thrombi in the right
cavities and the left pulmonary artery in the first patient and a thrombus in the
pulmonary artery trunk in the second patient. In the others cases, the diagnosis
was held by computed tomography angiography. All patients received thrombo-
lytic treatment by recombinant tissue plasminogen activator (rtPA) in 6 cases
and by streptokinase in one case with favourable outcome in all cases.
Conclusion: Massive pulmonary embolism is a life threatening pathology
with a high mortality over 20%. Thrombolysis is one of therapy ways that
leads to a lower rate of death.
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Objective: To determine the value, limitations and complications of
thrombolysis in pulmonary embolism. 
Patients and methods: This is a descriptive study of all patients admitted
to the cardiology department of CHU Ibn Rushd from 2009 to 2011 with pul-
monary embolism confirmed by echocardiography and chest CT angiography. 
Result: these 68 patients with a mean age of 49 months or over 19 years
with a female. 
The styles of pulmonary embolism vary widely with the management is
different. 
5% of patients with pulmonary embolism occurs in cardiac arrest and fibri-
nolysis offers better benefits and has no indication cons. 
10 to 20% of pulmonary embolism with hemodynamic instability occurs
PAS ≤ 90 mmHg or respiratory distress Quick Installation fibrinolysis in these
patients provides better clinical improvement and ultrasound. 
Pulmonary embolism at low risk and intermediate risk shows no indication
for fibrinolysis using simple anticoagulation. The rate of cerebral hemorrhage
is zero, 5 cases of gastrointestinal bleeding under control, intra-hospital
overall mortality is about 7%. 
Conclusion: This series demonstrates the value of thrombolysis on the dis-
solution of stones in the pulmonary arteries and hemodynamic parameters as
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